Liquid Biopsy Transcriptomics of Extracellular Vesicles (EV)
in Plasma of Pancreatic Ductal Adenocarcinoma (PDAC)
Jonathan Kim1, Vahid Bahrambeigi1, Vittorio Branchi1, Paola A. Guerrero1, Anirban Maitra1
1Department

of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Introduction

Pancreatic ductal adenocarcinoma (PDAC), the most common
and aggressive pancreatic cancer, has a poor prognosis with a
5-year survival rate of 4% because of difficult early diagnosis
and lack of response to treatment. Subtyping PDAC based on
molecular characteristics is potentially the key to individualized
patient stratification, providing more accurate prognostication
and optimization of therapeutic approaches over time. Two
RNA-derived molecular subtypes of PDAC have emerged as
‘classical’ or ‘basal-like’ [1]. In addition, recent findings have
shown intratumoral heterogeneity of PDAC through
transcriptomic profiling, having a mix of the molecular subtypes
within the same tissue. Tumor biopsy through EUS-FNA
(endoscopic ultrasound-guided fine-needle aspiration biopsy) is
currently the golden standard to confirm diagnosis in PDAC
patients. However, this procedure is invasive and often provides
limited information due to tumor heterogeneity. On the other
hand, liquid biopsy is a minimally invasive method for the realtime monitoring of cancer-derived biomarkers. Among liquid
biopsy biomarkers, extracellular vesicles (EVs) have a unique
potential because they possess nucleic acids [2]. Therefore,
using (EVs) could represent an alternative approach to
characterize cancer molecular profiles of PDAC patients. In this
study, we aim to perform a molecular classification of 7 PDAC
tumors through EV transcriptome analysis.

Materials & Methods
•

A.

RNA was extracted using the Invitrogen Total Exosome RNA
and Protein Isolation Kit. Takara SMART-Seq® v4 Ultra® Low
Input RNA Kit was used for cDNA synthesis.

•

Libraries were prepared using Illumina Nextera XT DNA
Library Prep Kit and sequenced by Illumina NextSeq 550.

•

Raw reads were demultiplexed and coding reads were used
for the deconvolution by DeMixT [3].

•

Deep Cancer subtype classification (Deepcc) framework,
based on artificial neural networks (ANN), was used to
classify molecular subtypes of plasma EV samples based on
a TCGA-ANN model [4]. CMScaller with Moffitt template was
used to assign a molecular subtype for each TCGA sample.
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In this study, we utilized ANN to predict the
molecular subtypes present in PDAC patients
derived from bulk transcriptome of liquid
biopsies.

•

Using a small cohort of 7 samples, we were
able to show that the RNA encapsulated in
plasma extracellular vesicles can effectively
recapitulate PDAC molecular subtypes
identified in tissue, which are based on the
molecular subtype framework by Moffit et al.

•

Moving forward, we will expand these studies
to a larger cohort and compare the
transcriptome of plasma EVs with bulk
RNAseq from matching resected tissues of
PDAC patients.

•

By identifying the tumor molecular landscape
from liquid biopsies, we hope to evaluate
treatment response and the characterization
of the cancer molecular profiles in a minimally
invasive manner.
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Figure 1. Workflow Overview. Plasma was extracted from whole blood
samples of seven PDAC patients. Next, plasma RNA was isolated,
washed, and converted to cDNA for amplification. Finally, the cDNA library
was prepared for next generation sequencing.

B.

Figure 2. Deconvolution and Classification Pipeline. (A) Tumor biopsies were performed through EUS-FNA. Plasma EVs
were isolated from PDAC patients and healthy controls. (B) Deconvolution on transcriptomic data through DeMixT model to
remove transcripts from normal EVs. (C) Creation of the functional spectrum based on gene set enrichment analysis as the
model for a deep learning framework of molecular pathways of PDAC subtypes.

Plasma EVs from seven PDAC patients and seven sex/age
matched healthy individuals were isolated through
ultracentrifugation.

•
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Liquid Biopsy vs.
Single Cell Molecular Subtypes

Figure 3. Molecular classifications of PDAC single cells and liquid biopsy. (A) UMAP plot of single cells from
biopsy samples. (B) Classical and basal-like molecular subtypes identified in the epithelial sub cluster from 3A. (C)
Clustered heatmap of 136 TCGA primary tumor samples, with samples sorted horizontally by classification. (D)
Comparison of molecular subtypes between liquid biopsies and paired tissue. An 86% (6/7) was detected between
both compartments.
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